drugset / Trial / NCT04329624

Effect Levosimendan Administration on Postoperative NT-proBNP in Cardiac Risk Patients

NCT04329624

Phase 3 Completed 230 enrolled Medical University of Vienna
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a prospective randomised trial investigating the effect of a preemptive administration of levosimendan on postoperative cardiac NT-proBNP concentrations.

Timeline

Start
2020-10-10
Primary completion
2023-11-07
Completion
2024-12-18

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Levosimendan Other / unclassified 12.5 mg

Indications

No indication recorded.